{"ticker": {"uuid": "c3a1b4db-d1a5-47db-9ae2-1b33c6761682", "symbol": "IMNM", "name": "Immunome\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data", "summary": "Immunome (IMNM) shares dropped 8.2% despite the FDA accepting its New Drug Application (NDA) for varegacestat, a gamma secretase inhibitor for desmoid tumors, with a PDUFA target date of April 28, 2027. The acceptance is based on strong Phase 3 data showing significant improvemen", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/why-immunome-imnm-is-down-82-after-fda-accepts-varegacestat", "source_name": "Simply Wall Street", "published_at": "2026-07-16T23:10:06", "published_display": "16 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What Do Recent Insider Sales at Immunome (IMNM) Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNZ2dkZGo0b0x4ZUhKZG5peFpfYUtBWjBqS2tuWVVVTi1wWFU1M09Pc2JEaDZjQjRKMUpIY3hWVzZHVWt0LXBnMVN5dmpBTHc4eHdlNlBrYXRnVTd5ekxtMDlTbHg3TVo2LWluWnJHUWlybHhVUUxoRFRRd01OY1l6WXFiVnZWMDNrOVl5dDZlbTc?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T12:21:18+00:00", "published_display": "16 Jul 2026 12:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What This Immunome Sale Means a Day Before a Big FDA Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOR2RMZzc2X3pKQmZSNmtIUUZmZF9FTjRFU2t6LVhYaGgxNDBwdzJjZVp3SThLblJzS3FUYWFMNmw1RXlIem5BbFVGcUtsTGxDd1pxN0lXcWZKLWZ4LVRaWFpfNWdrdmRYeUEtc1NHc3ZzQjhsNnJycHV1bldlU3ZzT1hUb3g5Nl9QTng4U1BVZldrdjVrS3FfMXo1eGZRdktwcUVrTmNxbDliU0QyQ0otT3h3?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-12T21:44:00+00:00", "published_display": "12 Jul 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains Immunome(IMNM.US) With Buy Rating", "summary": "Truist Financial has reiterated its Buy rating on Immunome (IMNM.US). This suggests a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72720179/truist-financial-maintains-immunome-imnmus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-10T17:09:31", "published_display": "10 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors", "summary": "Immunome (IMNM) shares rose 11.7% after the FDA accepted its New Drug Application (NDA) for varegacestat, a treatment for desmoid tumors. The NDA, with a PDUFA target action date of April 28, 2027, is based on Phase 3 data showing an 84% reduction in risk of progression or death.", "url": "https://www.sahmcapital.com/news/content/why-immunome-imnm-is-up-117-after-fda-accepts-varegacestat-nda-for-desmoid-tumors-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:40:46", "published_display": "10 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Stock Up 32% in a Month: Here's What You Should Know", "summary": "Immunome (IMNM) shares have risen 32% in the last month, driven by investor confidence in its lead asset, varegacestat, and broader clinical progress. The FDA has accepted Immunome's new drug application for varegacestat for desmoid tumors, with a decision expected by April 28, 2", "url": "https://sg.finance.yahoo.com/news/immunome-stock-32-month-heres-144000193.html", "source_name": "Market source", "published_at": "2026-07-10T15:40:07", "published_display": "10 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome CBO Horn Kinney sells $27,300 in stock", "summary": "Immunome Inc.'s Chief Business Officer, Horn Kinney, sold 1,092 shares of common stock for $27,300 after exercising employee stock options. This sale followed a 172% return on the stock over the past year, though InvestingPro analyses suggest the stock is overvalued. Kinney now h", "url": "https://www.investing.com/news/insider-trading-news/immunome-cbo-horn-kinney-sells-27300-in-stock-93CH-4785093", "source_name": "Investing.com", "published_at": "2026-07-10T05:40:57", "published_display": "10 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunome Inc For: 9 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Immunome Inc. on July 9. The main content is a brief statement, with the majority of the page consisting of navigation, market data, and related news headlines. The article itself is very minimalist, providing l", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunomeinc-for-9-july-93CH-2594040", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T02:40:07", "published_display": "10 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Inc. (IMNM) CBO exercises options and sells 1,092 shares", "summary": "Immunome Inc.'s Chief Business Officer, Horn Kinney, exercised employee stock options to acquire 1,092 shares at $12.92 per share and subsequently sold all 1,092 shares at $25.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on Ma", "url": "https://www.stocktitan.net/sec-filings/IMNM/form-4-immunome-inc-insider-trading-activity-84b7ac0b6cd1.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:39:44", "published_display": "09 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Immunome stock rating on FDA filing By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Immunome Inc. (NASDAQ:IMNM) following the FDA\u2019s acceptance of its new drug application for varegacestat. The company's stock has seen a significant 170% gain over the past year, with ongoing positive analys", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-immunome-stock-rating-on-fda-filing-93CH-2592919", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T12:10:11", "published_display": "09 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review", "summary": "Immunome (NASDAQ: IMNM) announced that the FDA has accepted its New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor, for treating desmoid tumors. The FDA has set a target action date of April 28, 2027. Clinical data from the Phase 3 RINGSIDE trial showe", "url": "https://www.benzinga.com/news/health-care/26/07/60340757/immunome-clears-key-regulatory-milestone-as-lead-drug-goes-under-fda-review", "source_name": "Benzinga", "published_at": "2026-07-08T17:40:52", "published_display": "08 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision", "summary": "The FDA has accepted Immunome's New Drug Application (NDA) for varegacestat, an investigational oral gamma secretase inhibitor, for adult patients with desmoid tumors, setting an April 28, 2027, PDUFA action date. This decision is based on strong results from the Phase 3 RINGSIDE", "url": "https://oncodaily.com/techology/varegacestat537826", "source_name": "Oncodaily", "published_at": "2026-07-08T17:40:52", "published_display": "08 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40", "summary": "LifeSci Capital has reiterated its Buy rating for Immunome (IMNM.US) and maintained a target price of $40. This indicates continued confidence in the company's prospects from the analyst firm. Investors will likely watch Immunome's performance in light of this maintained positive", "url": "https://www.moomoo.com/news/post/72659090/lifesci-capital-maintains-immunome-imnmus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-08T17:10:12", "published_display": "08 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors", "summary": "Immunome, Inc. announced that the U.S. FDA has accepted its New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 20", "url": "https://www.caledonianrecord.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment/article_09c9bc04-27a2-54f4-afef-569d84adedaa.html", "source_name": "Caledonian Record", "published_at": "2026-07-08T17:10:12", "published_display": "08 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome granted FDA review for tumor candidate (IMNM:NASDAQ)", "summary": "Immunome Inc. (IMNM) announced that the U.S. FDA has accepted its marketing application for varegacestat, a drug developed to treat desmoid tumors. This marks a significant step for the company's lead asset. The application is targeted specifically at adult patients suffering fro", "url": "https://seekingalpha.com/news/4612281-immunome-granted-fda-review-for-tumor-candidate", "source_name": "Seeking Alpha", "published_at": "2026-07-08T13:39:39", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Says FDA Accepted NDA for Desmoid Tumors Drug", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immunome-says-fda-accepted-nda-120601946.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:06:01+00:00", "published_display": "08 Jul 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome secures FDA review for cancer drug varegacestat", "summary": "Immunome's oral tumor treatment, varegacestat, has been accepted for New Drug Application review by the FDA after showing an 84% reduction in the risk of disease progression or death in Phase 3 trials. The FDA has set a Prescription Drug User Fee Act target action date of April 2", "url": "https://grafa.com/en/news/united-states/immunome-fda-nda-acceptance-varegacestat-tumor", "source_name": "grafa.com", "published_at": "2026-07-08T11:55:00", "published_display": "08 Jul 2026 11:55", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-073435415.html", "source_name": "MT Newswires", "published_at": "2026-07-08T07:34:35+00:00", "published_display": "08 Jul 2026 07:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome\u2019s desmoid tumor drug wins FDA review, April 2027 date set", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQYklOcVhlUjU0cjFrc0tmUEVmTXB3SXNORVVsVGZnVXVDUWVmZ0RjN2FoZnpVOENiRzVOUDdwSmNBMUZ3TkRQeDNXa3VUZkNySm1PczZRNzhlaGJuUy1QQUx2cnRxMlVTUDZ3QUw1bUFxYkhPOVlkWEdtQmVNMnJjbGdPa2hKajc1VUFLc2pKeFRsbDN4ZEF3djJvbUhVVnc3VDVGRThXX1RlenNwemNOTDJkNzhOOXN4aDRhbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (IMNM) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis of Immunome Inc. (NASDAQ: IMNM) for rule-based trading strategies, highlighting strong sentiment across all horizons and significant risk-reward opportunities. It details specific trading strategies for different risk profiles, includ", "url": "https://news.stocktradersdaily.com/news_release/149/Price-Driven_Insight_from_IMNM_for_Rule-Based_Strategy_070826045202_1783500722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T04:52:00", "published_display": "08 Jul 2026 04:52", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Immunome, Inc. announced that its Compensation Committee granted inducement awards consisting of non-statutory stock options to 17 new employees. These options cover an aggregate of 344,000 shares of common stock, with an exercise price of $21.49, vesting over four years accordin", "url": "https://www.businesswire.com/news/home/20260707694125/en/Immunome-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-07-08T04:40:52", "published_display": "08 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome (IMNM) CMO exercises 55K options and sells 55K shares under 10b5-1 plan", "summary": "Immunome Inc.'s Chief Medical Officer, Robert Lechleider, exercised 55,000 employee stock options at $8.73 per share on July 2, 2026. On the same day, he sold 55,000 common shares in open-market transactions, averaging prices between $21.95 and $23.44 per share, as part of a pre-", "url": "https://www.stocktitan.net/sec-filings/IMNM/form-4-immunome-inc-insider-trading-activity-4869425c3d4b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T04:11:27", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome CMO Robert Lechleider sells $1.24m in company stock", "summary": "Immunome Inc.'s Chief Medical Officer, Robert Lechleider, sold 55,000 shares of company stock for $1,244,330, following the exercise of employee stock options. The transactions were conducted under a Rule 10b5-1 trading plan, and analysts largely maintain bullish price targets fo", "url": "https://www.investing.com/news/insider-trading-news/immunome-cmo-robert-lechleider-sells-124m-in-company-stock-93CH-4780420", "source_name": "Investing.com", "published_at": "2026-07-08T04:11:27", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 7, 2026", "summary": "Immunome, Inc. announced inducement grants of non-statutory stock options for 344,000 shares to seventeen new employees. These awards, approved by the Compensation Committee on July 1, 2026, fall under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The op", "url": "https://www.biospace.com/press-releases/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-july-7-2026", "source_name": "BioSpace", "published_at": "2026-07-08T03:36:27", "published_display": "08 Jul 2026 03:36", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome director Isaac Barchas sells $2.4m in shares, price $24.11-$24.20", "summary": "Immunome Inc. Director Isaac Barchas sold 100,000 shares of common stock for approximately $2.4 million across two transactions on July 6 and July 7, 2026, with prices ranging from $24.11 to $24.20 per share. These sales were executed via a Rule 10b5-1 trading plan after the stoc", "url": "https://www.investing.com/news/insider-trading-news/immunome-director-isaac-barchas-sells-24m-in-shares-price-24112420-93CH-4780531", "source_name": "Investing.com", "published_at": "2026-07-08T00:11:27", "published_display": "08 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entity tied to Immunome (IMNM) director sells 100K shares", "summary": "An entity associated with Immunome (IMNM) director Isaac Barchas, AMBHMC II LLC, sold 100,000 shares of the company's common stock on July 6 and 7, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices of approximately $24.11", "url": "https://www.stocktitan.net/sec-filings/IMNM/form-4-immunome-inc-insider-trading-activity-ce6698206970.html", "source_name": "Stock Titan", "published_at": "2026-07-08T00:11:27", "published_display": "08 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $1,244,331, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-214758995.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:47:58+00:00", "published_display": "07 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunome Inc For: 7 July By Investing.com", "summary": "Investing.com reports on a Form 4 filing for Immunome Inc. on July 7th, 2026. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article itself simply states the filing event without providing additional detail", "url": "https://ca.investing.com/news/stock-market-news/form-4-immunomeinc-for-7-july-93CH-4724135", "source_name": "Investing.com Canada", "published_at": "2026-07-07T22:11:27", "published_display": "07 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Immunome Inc. SEC Filing", "summary": "This article reports on an SEC Form 144 filing by Immunome Inc. (IMNM), indicating a proposed sale of securities. The filing details the filer information, issuer information, securities to be sold (common stock acquired via stock option exercise), and the broker involved. The do", "url": "https://www.stocktitan.net/sec-filings/IMNM/144-immunome-inc-sec-filing-340e9d4fc05c.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:27", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome lures 17 new hires with 344,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQa1FwMVF0SWoyeTMwNmZUbm9lVVJ4MzdPNlNrWmI3V2Joai1PcjBaXzZDLUhpdnFmUS1Zd0Rsd2FOS1cyaDdwWk1HVVVnTGthYm9uTk5vX1ZTSzVxTmhKUTkwVE5lclJRUi1MQ296cF9WbmdNTkJEaVhEYU9iWXhfUnR5VzFaNFhBVnVUc3RBYVlPdVNYVmhibi1HR3l1NzJ2d0hqOFRYcmY3dkdLT3FhZmRNRnRiVF9JaWhRTzJrVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Immunome For: 6 July By Investing.com", "summary": "The article is a brief financial update from Investing.com, stating \"Form 144 Immunome For: 6 July\". It includes the stock symbol IMNM and notes a 1.23% increase. The content appears to be a placeholder or a very short news item, possibly indicating an SEC filing.", "url": "https://ca.investing.com/news/stock-market-news/form-144-immunome-for-6-july-93CH-4721847", "source_name": "Investing.com Canada", "published_at": "2026-07-06T22:09:29", "published_display": "06 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM (Nasdaq) affiliate filings report multiple share sales, including 100,000-share entries", "summary": "Immunome Inc. (IMNM) affiliates have filed Form 144s reporting multiple share sales. These filings indicate an intended sale of 100,000 shares from a private placement dating back to October 2023, and recent sales including two 100,000-share entries and one 1,050-share entry by e", "url": "https://www.stocktitan.net/sec-filings/IMNM/144-immunome-inc-sec-filing-7bd4b0a48bd6.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:09:29", "published_display": "06 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome(IMNM.US) Director Sells US$4.39 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ1EzMWo3NWU5dnF2QzJkM0VVUXl0NklhQV9QWFkxS2twM2pDX285M3NJVEtmS0ZoRThGSU91RkNRaURpYkhLdWVjckJIZWR4Uy1NQ2RkSXhBOHJtbTB2VTg0anRuZUJnWjdEZkhSTXNWZ2l0Qm0wYXhRSTBQU2JUV3N4cmZ4dU1lbW1zcVNWLVRud1drMDM3RkVieVZlbEU?oc=5", "source_name": "Moomoo", "published_at": "2026-07-03T03:13:56+00:00", "published_display": "03 Jul 2026 03:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked entities trim Immunome (IMNM) stake with 201,050-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcGVWMV9OUFFvaGRfY0tGSjdzSzM2OXU3LVVDUlNfalhMdHNjZ19UcWNxd09zV3IyX0JoZFc1UWNMVWx2Um5BenZQZXFaUThyMVU2QnRNS2tKaEl3S0JrTm5aRThQSTlpb3NieEtDSERnY0t0akNzeFhnNWpRaGpjbnlGZGFyVFVDbmJzRE9lM0hFQjRXcDJ2cGVtVzBtbGY0Q1NxeDQ5amVudw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM (Nasdaq: IMNM) Rule 144 entries show 100,000-share block", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNRmxlc2NaVkZ6aVNTWFF1Zy1jeWxvSlVMX2NxaEc2ZUF3UTY2UGNrVVhwcUZxNy15TUZWSWdTWEZXa0xoeGdkYUlhSllONzMzNEsyclB6TUNkZnhid2o4aWRnMFBUTE1aVzY5eVRMc0YtdU9zX3FVVDg3bU5nWDhCRWpkeWpma0EyQmtQOTJrRkQxTGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM (NASDAQ: IMNM) affiliate files to sell 55,000 shares on 07/02/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPQmRCZ1FJWVFMU1V0b3prcnZhQWpGLVRxQ0gySUxtcTR2Q24zcWZ2b05BWml5YzBXOXVNTVFoRnp2OEk3bGdHUktLNDA3R282dW1CbTdLOXROdzhZQW4tWG9JeVZsODc3Y25oR2w0MjRzb3JiYnByUmtFQVo0cXZidkR6MllKZERuSVlhT2VaUm1ReVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunome\u2019s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T05:44:07+00:00", "published_display": "02 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome (IMNM) After Russell Index Removal Still Looks Cheap On Fair Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $1,091,662, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-210011084.html", "source_name": "MT Newswires", "published_at": "2026-06-29T21:00:11+00:00", "published_display": "29 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome (IMNM) CMO sells 55K shares after exercising options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVHNMdmJuaTVKSGs4M2I5bG02X3lqRzJHNzdQdlZ3c0M3bjhkanlvRk1kUTdXWjNaeXI1cmUyTlFFN0JOYTZfUFlTU3lSNjJBcE9zNWVZUGw0RmxPYWVoY1FZbV9vbl9qclo5T01MUnpWalFIeW4zNVFNZjVvQzBrZHh3OWEtZUJYdmhXbXpzNlVKeDZXeDBDZnB2WE9zNzNwWXZBeGI1NC1wUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $1,093,800, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-213323638.html", "source_name": "MT Newswires", "published_at": "2026-06-17T21:33:23+00:00", "published_display": "17 Jun 2026 21:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Says First Patient Dosed in Phase 1 Trial of IM-1617 in Advanced Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immunome-says-first-patient-dosed-115404057.html", "source_name": "MT Newswires", "published_at": "2026-06-11T11:54:04+00:00", "published_display": "11 Jun 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM - Immunome Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE5hclRNeWpXTjNDczdmTWFGYnF2MnJmQ1dKVElxWG94dk55Sk1Ba2JGMmxPN0Z2Z2JpZmpTTnlfQWRxMU5EU2c?oc=5", "source_name": "Finviz", "published_at": "2026-05-26T14:31:04+00:00", "published_display": "26 May 2026 14:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Offers Immunome (IMNM) a Compelling Investment Opportunity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPeWVTVlFnUGE5NlNyamE2N2wwYVVud21VZG1GZm5UdXY1QlZndlpvTU8tcmFOT28zcEJMdExSZk03V3hNaFJKMEQtNXBZU3VmOHB4UnE2d1ZiZ1hzMmF5Uy1aVFBqaXhXXzNUUEJkNXhsUjFGRldrZnRDMXVPbmFzbzBPVUhISEZFa3VGdWRqRmNnOW5lb2NTazVWdjJsbHYxSmd5Zmx0aE1nc0x1NExwQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxOVVVYdXN0cUU5X2I2ZlJQTEh6LWJmSzR4bVlkT3pGZ0FUZjY0SUhFdFI3N2FiZ2FmZ1p5YWwwVUsyX0NWWVJCTzFiS19iTEgyUDE3SDJVTUdRMGNNc0Q4bXpHRWVTREpWZHhpc281S2FwYnE5dU9GaVd0ckxOVlFFVWdLeHJpaTN2R1JwbHpyQzViekJXU1lyY1YxZmVSNnNra282eTJfdzFaV3JEcTl5YlRqWTFXdkRvWV9seEVvNk5Gb1hBaS1SSlJnNXd4MTJyeHRMYnNKaWtKdE9talJReW44RHc2elROa0N4VkNBR1VjWFVlYUFKYmdlQWZfaXg2Z092MWNEb1YxR3huemd6dGR6eG1uQQ?oc=5", "source_name": "Business Wire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVXZmQVp5S1FKVi03dzg1Z1FVLWM4WXpiRDRJOExQOXJHdFpGdGdQVXpIZWN0V0RUbWRicEQ0dlZFVkt1U3A0ekZseUVvOW9uMFNJVjNrczJaUEVJZUFJNnhWb2lNa1F2RGRTQkV1aS1xZm9jMXdWU3AxYkRvLU5UTXJxMzBHY25GcmlkcUM1NEZnMDNqcjFF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seven new Immunome hires get options on 282,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOLUpXRHZ0Z2dyYlczdzVPRkw5VEg1UkRyRnVHdjJuQVlzellWNGc4djNybTA2eEZNb21nZjBsZjh5ZmFaVHRDT1VjQU1TUWpJMHVZbmtzQjh1RTVxZEt0TU1FeFlVbkt2TWp1R2tZLTJibzRzXzdLYnFHVnVXMHI5UUpTTzVqRHBPQXV5cVdVMXp3SzFCSUNjNEZSbkp5bjlxZThWLVlfdDF1VUMxTHk4TDRYQkdrNmdaRUh5SHlHZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQbHJpWHhFZGFSUFJCcnZUelRvX3NKY2JxUXpTZW1rMjVaMXVmTUd1RXgzVTFyR3JhamJVeUVuVTd1bG9kU0M1X2VXSm9xWm1tM0JJTWItMWd4eG5PQTJlNkdJZ2UybGljOEoxVEx5ZGhYbVZ6ZXMwWjJOb1hlUmh2b2tB?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data", "summary": "Immunome (IMNM) shares dropped 8.2% despite the FDA accepting its New Drug Application (NDA) for varegacestat, a gamma secretase inhibitor for desmoid tumors, with a PDUFA target date of April 28, 2027. The acceptance is based on strong Phase 3 data showing significant improvemen", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imnm/immunome/news/why-immunome-imnm-is-down-82-after-fda-accepts-varegacestat", "source_name": "Simply Wall Street", "published_at": "2026-07-16T23:10:06", "published_display": "16 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Do Recent Insider Sales at Immunome (IMNM) Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNZ2dkZGo0b0x4ZUhKZG5peFpfYUtBWjBqS2tuWVVVTi1wWFU1M09Pc2JEaDZjQjRKMUpIY3hWVzZHVWt0LXBnMVN5dmpBTHc4eHdlNlBrYXRnVTd5ekxtMDlTbHg3TVo2LWluWnJHUWlybHhVUUxoRFRRd01OY1l6WXFiVnZWMDNrOVl5dDZlbTc?oc=5", "source_name": "Kavout | AI", "published_at": "2026-07-16T12:21:18+00:00", "published_display": "16 Jul 2026 12:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What This Immunome Sale Means a Day Before a Big FDA Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOR2RMZzc2X3pKQmZSNmtIUUZmZF9FTjRFU2t6LVhYaGgxNDBwdzJjZVp3SThLblJzS3FUYWFMNmw1RXlIem5BbFVGcUtsTGxDd1pxN0lXcWZKLWZ4LVRaWFpfNWdrdmRYeUEtc1NHc3ZzQjhsNnJycHV1bldlU3ZzT1hUb3g5Nl9QTng4U1BVZldrdjVrS3FfMXo1eGZRdktwcUVrTmNxbDliU0QyQ0otT3h3?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-12T21:44:00+00:00", "published_display": "12 Jul 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Maintains Immunome(IMNM.US) With Buy Rating", "summary": "Truist Financial has reiterated its Buy rating on Immunome (IMNM.US). This suggests a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72720179/truist-financial-maintains-immunome-imnmus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-10T17:09:31", "published_display": "10 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immunome (IMNM) Is Up 11.7% After FDA Accepts Varegacestat NDA For Desmoid Tumors", "summary": "Immunome (IMNM) shares rose 11.7% after the FDA accepted its New Drug Application (NDA) for varegacestat, a treatment for desmoid tumors. The NDA, with a PDUFA target action date of April 28, 2027, is based on Phase 3 data showing an 84% reduction in risk of progression or death.", "url": "https://www.sahmcapital.com/news/content/why-immunome-imnm-is-up-117-after-fda-accepts-varegacestat-nda-for-desmoid-tumors-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:40:46", "published_display": "10 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Stock Up 32% in a Month: Here's What You Should Know", "summary": "Immunome (IMNM) shares have risen 32% in the last month, driven by investor confidence in its lead asset, varegacestat, and broader clinical progress. The FDA has accepted Immunome's new drug application for varegacestat for desmoid tumors, with a decision expected by April 28, 2", "url": "https://sg.finance.yahoo.com/news/immunome-stock-32-month-heres-144000193.html", "source_name": "Market source", "published_at": "2026-07-10T15:40:07", "published_display": "10 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome CBO Horn Kinney sells $27,300 in stock", "summary": "Immunome Inc.'s Chief Business Officer, Horn Kinney, sold 1,092 shares of common stock for $27,300 after exercising employee stock options. This sale followed a 172% return on the stock over the past year, though InvestingPro analyses suggest the stock is overvalued. Kinney now h", "url": "https://www.investing.com/news/insider-trading-news/immunome-cbo-horn-kinney-sells-27300-in-stock-93CH-4785093", "source_name": "Investing.com", "published_at": "2026-07-10T05:40:57", "published_display": "10 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunome Inc For: 9 July By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Immunome Inc. on July 9. The main content is a brief statement, with the majority of the page consisting of navigation, market data, and related news headlines. The article itself is very minimalist, providing l", "url": "https://ng.investing.com/news/stock-market-news/form-4-immunomeinc-for-9-july-93CH-2594040", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T02:40:07", "published_display": "10 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Inc. (IMNM) CBO exercises options and sells 1,092 shares", "summary": "Immunome Inc.'s Chief Business Officer, Horn Kinney, exercised employee stock options to acquire 1,092 shares at $12.92 per share and subsequently sold all 1,092 shares at $25.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on Ma", "url": "https://www.stocktitan.net/sec-filings/IMNM/form-4-immunome-inc-insider-trading-activity-84b7ac0b6cd1.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:39:44", "published_display": "09 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Immunome stock rating on FDA filing By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Immunome Inc. (NASDAQ:IMNM) following the FDA\u2019s acceptance of its new drug application for varegacestat. The company's stock has seen a significant 170% gain over the past year, with ongoing positive analys", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-immunome-stock-rating-on-fda-filing-93CH-2592919", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T12:10:11", "published_display": "09 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review", "summary": "Immunome (NASDAQ: IMNM) announced that the FDA has accepted its New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor, for treating desmoid tumors. The FDA has set a target action date of April 28, 2027. Clinical data from the Phase 3 RINGSIDE trial showe", "url": "https://www.benzinga.com/news/health-care/26/07/60340757/immunome-clears-key-regulatory-milestone-as-lead-drug-goes-under-fda-review", "source_name": "Benzinga", "published_at": "2026-07-08T17:40:52", "published_display": "08 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision", "summary": "The FDA has accepted Immunome's New Drug Application (NDA) for varegacestat, an investigational oral gamma secretase inhibitor, for adult patients with desmoid tumors, setting an April 28, 2027, PDUFA action date. This decision is based on strong results from the Phase 3 RINGSIDE", "url": "https://oncodaily.com/techology/varegacestat537826", "source_name": "Oncodaily", "published_at": "2026-07-08T17:40:52", "published_display": "08 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40", "summary": "LifeSci Capital has reiterated its Buy rating for Immunome (IMNM.US) and maintained a target price of $40. This indicates continued confidence in the company's prospects from the analyst firm. Investors will likely watch Immunome's performance in light of this maintained positive", "url": "https://www.moomoo.com/news/post/72659090/lifesci-capital-maintains-immunome-imnmus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-08T17:10:12", "published_display": "08 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors", "summary": "Immunome, Inc. announced that the U.S. FDA has accepted its New Drug Application (NDA) for varegacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 20", "url": "https://www.caledonianrecord.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment/article_09c9bc04-27a2-54f4-afef-569d84adedaa.html", "source_name": "Caledonian Record", "published_at": "2026-07-08T17:10:12", "published_display": "08 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome granted FDA review for tumor candidate (IMNM:NASDAQ)", "summary": "Immunome Inc. (IMNM) announced that the U.S. FDA has accepted its marketing application for varegacestat, a drug developed to treat desmoid tumors. This marks a significant step for the company's lead asset. The application is targeted specifically at adult patients suffering fro", "url": "https://seekingalpha.com/news/4612281-immunome-granted-fda-review-for-tumor-candidate", "source_name": "Seeking Alpha", "published_at": "2026-07-08T13:39:39", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Says FDA Accepted NDA for Desmoid Tumors Drug", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/immunome-says-fda-accepted-nda-120601946.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:06:01+00:00", "published_display": "08 Jul 2026 12:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome secures FDA review for cancer drug varegacestat", "summary": "Immunome's oral tumor treatment, varegacestat, has been accepted for New Drug Application review by the FDA after showing an 84% reduction in the risk of disease progression or death in Phase 3 trials. The FDA has set a Prescription Drug User Fee Act target action date of April 2", "url": "https://grafa.com/en/news/united-states/immunome-fda-nda-acceptance-varegacestat-tumor", "source_name": "grafa.com", "published_at": "2026-07-08T11:55:00", "published_display": "08 Jul 2026 11:55", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-073435415.html", "source_name": "MT Newswires", "published_at": "2026-07-08T07:34:35+00:00", "published_display": "08 Jul 2026 07:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome\u2019s desmoid tumor drug wins FDA review, April 2027 date set", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQYklOcVhlUjU0cjFrc0tmUEVmTXB3SXNORVVsVGZnVXVDUWVmZ0RjN2FoZnpVOENiRzVOUDdwSmNBMUZ3TkRQeDNXa3VUZkNySm1PczZRNzhlaGJuUy1QQUx2cnRxMlVTUDZ3QUw1bUFxYkhPOVlkWEdtQmVNMnJjbGdPa2hKajc1VUFLc2pKeFRsbDN4ZEF3djJvbUhVVnc3VDVGRThXX1RlenNwemNOTDJkNzhOOXN4aDRhbQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price-Driven Insight from (IMNM) for Rule-Based Strategy", "summary": "This article provides a price-driven analysis of Immunome Inc. (NASDAQ: IMNM) for rule-based trading strategies, highlighting strong sentiment across all horizons and significant risk-reward opportunities. It details specific trading strategies for different risk profiles, includ", "url": "https://news.stocktradersdaily.com/news_release/149/Price-Driven_Insight_from_IMNM_for_Rule-Based_Strategy_070826045202_1783500722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T04:52:00", "published_display": "08 Jul 2026 04:52", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Immunome, Inc. announced that its Compensation Committee granted inducement awards consisting of non-statutory stock options to 17 new employees. These options cover an aggregate of 344,000 shares of common stock, with an exercise price of $21.49, vesting over four years accordin", "url": "https://www.businesswire.com/news/home/20260707694125/en/Immunome-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4", "source_name": "Business Wire", "published_at": "2026-07-08T04:40:52", "published_display": "08 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome (IMNM) CMO exercises 55K options and sells 55K shares under 10b5-1 plan", "summary": "Immunome Inc.'s Chief Medical Officer, Robert Lechleider, exercised 55,000 employee stock options at $8.73 per share on July 2, 2026. On the same day, he sold 55,000 common shares in open-market transactions, averaging prices between $21.95 and $23.44 per share, as part of a pre-", "url": "https://www.stocktitan.net/sec-filings/IMNM/form-4-immunome-inc-insider-trading-activity-4869425c3d4b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T04:11:27", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome CMO Robert Lechleider sells $1.24m in company stock", "summary": "Immunome Inc.'s Chief Medical Officer, Robert Lechleider, sold 55,000 shares of company stock for $1,244,330, following the exercise of employee stock options. The transactions were conducted under a Rule 10b5-1 trading plan, and analysts largely maintain bullish price targets fo", "url": "https://www.investing.com/news/insider-trading-news/immunome-cmo-robert-lechleider-sells-124m-in-company-stock-93CH-4780420", "source_name": "Investing.com", "published_at": "2026-07-08T04:11:27", "published_display": "08 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 7, 2026", "summary": "Immunome, Inc. announced inducement grants of non-statutory stock options for 344,000 shares to seventeen new employees. These awards, approved by the Compensation Committee on July 1, 2026, fall under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The op", "url": "https://www.biospace.com/press-releases/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-july-7-2026", "source_name": "BioSpace", "published_at": "2026-07-08T03:36:27", "published_display": "08 Jul 2026 03:36", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome director Isaac Barchas sells $2.4m in shares, price $24.11-$24.20", "summary": "Immunome Inc. Director Isaac Barchas sold 100,000 shares of common stock for approximately $2.4 million across two transactions on July 6 and July 7, 2026, with prices ranging from $24.11 to $24.20 per share. These sales were executed via a Rule 10b5-1 trading plan after the stoc", "url": "https://www.investing.com/news/insider-trading-news/immunome-director-isaac-barchas-sells-24m-in-shares-price-24112420-93CH-4780531", "source_name": "Investing.com", "published_at": "2026-07-08T00:11:27", "published_display": "08 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Entity tied to Immunome (IMNM) director sells 100K shares", "summary": "An entity associated with Immunome (IMNM) director Isaac Barchas, AMBHMC II LLC, sold 100,000 shares of the company's common stock on July 6 and 7, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, occurred at weighted average prices of approximately $24.11", "url": "https://www.stocktitan.net/sec-filings/IMNM/form-4-immunome-inc-insider-trading-activity-ce6698206970.html", "source_name": "Stock Titan", "published_at": "2026-07-08T00:11:27", "published_display": "08 Jul 2026 00:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $1,244,331, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-214758995.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:47:58+00:00", "published_display": "07 Jul 2026 21:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Immunome Inc For: 7 July By Investing.com", "summary": "Investing.com reports on a Form 4 filing for Immunome Inc. on July 7th, 2026. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article itself simply states the filing event without providing additional detail", "url": "https://ca.investing.com/news/stock-market-news/form-4-immunomeinc-for-7-july-93CH-4724135", "source_name": "Investing.com Canada", "published_at": "2026-07-07T22:11:27", "published_display": "07 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Immunome Inc. SEC Filing", "summary": "This article reports on an SEC Form 144 filing by Immunome Inc. (IMNM), indicating a proposed sale of securities. The filing details the filer information, issuer information, securities to be sold (common stock acquired via stock option exercise), and the broker involved. The do", "url": "https://www.stocktitan.net/sec-filings/IMNM/144-immunome-inc-sec-filing-340e9d4fc05c.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:11:27", "published_display": "07 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome lures 17 new hires with 344,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQa1FwMVF0SWoyeTMwNmZUbm9lVVJ4MzdPNlNrWmI3V2Joai1PcjBaXzZDLUhpdnFmUS1Zd0Rsd2FOS1cyaDdwWk1HVVVnTGthYm9uTk5vX1ZTSzVxTmhKUTkwVE5lclJRUi1MQ296cF9WbmdNTkJEaVhEYU9iWXhfUnR5VzFaNFhBVnVUc3RBYVlPdVNYVmhibi1HR3l1NzJ2d0hqOFRYcmY3dkdLT3FhZmRNRnRiVF9JaWhRTzJrVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Immunome For: 6 July By Investing.com", "summary": "The article is a brief financial update from Investing.com, stating \"Form 144 Immunome For: 6 July\". It includes the stock symbol IMNM and notes a 1.23% increase. The content appears to be a placeholder or a very short news item, possibly indicating an SEC filing.", "url": "https://ca.investing.com/news/stock-market-news/form-144-immunome-for-6-july-93CH-4721847", "source_name": "Investing.com Canada", "published_at": "2026-07-06T22:09:29", "published_display": "06 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM (Nasdaq) affiliate filings report multiple share sales, including 100,000-share entries", "summary": "Immunome Inc. (IMNM) affiliates have filed Form 144s reporting multiple share sales. These filings indicate an intended sale of 100,000 shares from a private placement dating back to October 2023, and recent sales including two 100,000-share entries and one 1,050-share entry by e", "url": "https://www.stocktitan.net/sec-filings/IMNM/144-immunome-inc-sec-filing-7bd4b0a48bd6.html", "source_name": "Stock Titan", "published_at": "2026-07-06T21:09:29", "published_display": "06 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome(IMNM.US) Director Sells US$4.39 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ1EzMWo3NWU5dnF2QzJkM0VVUXl0NklhQV9QWFkxS2twM2pDX285M3NJVEtmS0ZoRThGSU91RkNRaURpYkhLdWVjckJIZWR4Uy1NQ2RkSXhBOHJtbTB2VTg0anRuZUJnWjdEZkhSTXNWZ2l0Qm0wYXhRSTBQU2JUV3N4cmZ4dU1lbW1zcVNWLVRud1drMDM3RkVieVZlbEU?oc=5", "source_name": "Moomoo", "published_at": "2026-07-03T03:13:56+00:00", "published_display": "03 Jul 2026 03:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked entities trim Immunome (IMNM) stake with 201,050-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcGVWMV9OUFFvaGRfY0tGSjdzSzM2OXU3LVVDUlNfalhMdHNjZ19UcWNxd09zV3IyX0JoZFc1UWNMVWx2Um5BenZQZXFaUThyMVU2QnRNS2tKaEl3S0JrTm5aRThQSTlpb3NieEtDSERnY0t0akNzeFhnNWpRaGpjbnlGZGFyVFVDbmJzRE9lM0hFQjRXcDJ2cGVtVzBtbGY0Q1NxeDQ5amVudw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM (Nasdaq: IMNM) Rule 144 entries show 100,000-share block", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNRmxlc2NaVkZ6aVNTWFF1Zy1jeWxvSlVMX2NxaEc2ZUF3UTY2UGNrVVhwcUZxNy15TUZWSWdTWEZXa0xoeGdkYUlhSllONzMzNEsyclB6TUNkZnhid2o4aWRnMFBUTE1aVzY5eVRMc0YtdU9zX3FVVDg3bU5nWDhCRWpkeWpma0EyQmtQOTJrRkQxTGc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM (NASDAQ: IMNM) affiliate files to sell 55,000 shares on 07/02/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPQmRCZ1FJWVFMU1V0b3prcnZhQWpGLVRxQ0gySUxtcTR2Q24zcWZ2b05BWml5YzBXOXVNTVFoRnp2OEk3bGdHUktLNDA3R282dW1CbTdLOXROdzhZQW4tWG9JeVZsODc3Y25oR2w0MjRzb3JiYnByUmtFQVo0cXZidkR6MllKZERuSVlhT2VaUm1ReVU?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunome\u2019s (IMNM) Russell Exit Quietly Recasting Its Shareholder Base And Liquidity Story?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-02T05:44:07+00:00", "published_display": "02 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome (IMNM) After Russell Index Removal Still Looks Cheap On Fair Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $1,091,662, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-210011084.html", "source_name": "MT Newswires", "published_at": "2026-06-29T21:00:11+00:00", "published_display": "29 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome (IMNM) CMO sells 55K shares after exercising options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVHNMdmJuaTVKSGs4M2I5bG02X3lqRzJHNzdQdlZ3c0M3bjhkanlvRk1kUTdXWjNaeXI1cmUyTlFFN0JOYTZfUFlTU3lSNjJBcE9zNWVZUGw0RmxPYWVoY1FZbV9vbl9qclo5T01MUnpWalFIeW4zNVFNZjVvQzBrZHh3OWEtZUJYdmhXbXpzNlVKeDZXeDBDZnB2WE9zNzNwWXZBeGI1NC1wUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Insider Sold Shares Worth $1,093,800, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immunome-insider-sold-shares-worth-213323638.html", "source_name": "MT Newswires", "published_at": "2026-06-17T21:33:23+00:00", "published_display": "17 Jun 2026 21:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Says First Patient Dosed in Phase 1 Trial of IM-1617 in Advanced Solid Tumors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immunome-says-first-patient-dosed-115404057.html", "source_name": "MT Newswires", "published_at": "2026-06-11T11:54:04+00:00", "published_display": "11 Jun 2026 11:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMNM - Immunome Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTE5hclRNeWpXTjNDczdmTWFGYnF2MnJmQ1dKVElxWG94dk55Sk1Ba2JGMmxPN0Z2Z2JpZmpTTnlfQWRxMU5EU2c?oc=5", "source_name": "Finviz", "published_at": "2026-05-26T14:31:04+00:00", "published_display": "26 May 2026 14:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Offers Immunome (IMNM) a Compelling Investment Opportunity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPeWVTVlFnUGE5NlNyamE2N2wwYVVud21VZG1GZm5UdXY1QlZndlpvTU8tcmFOT28zcEJMdExSZk03V3hNaFJKMEQtNXBZU3VmOHB4UnE2d1ZiZ1hzMmF5Uy1aVFBqaXhXXzNUUEJkNXhsUjFGRldrZnRDMXVPbmFzbzBPVUhISEZFa3VGdWRqRmNnOW5lb2NTazVWdjJsbHYxSmd5Zmx0aE1nc0x1NExwQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgJBVV95cUxOVVVYdXN0cUU5X2I2ZlJQTEh6LWJmSzR4bVlkT3pGZ0FUZjY0SUhFdFI3N2FiZ2FmZ1p5YWwwVUsyX0NWWVJCTzFiS19iTEgyUDE3SDJVTUdRMGNNc0Q4bXpHRWVTREpWZHhpc281S2FwYnE5dU9GaVd0ckxOVlFFVWdLeHJpaTN2R1JwbHpyQzViekJXU1lyY1YxZmVSNnNra282eTJfdzFaV3JEcTl5YlRqWTFXdkRvWV9seEVvNk5Gb1hBaS1SSlJnNXd4MTJyeHRMYnNKaWtKdE9talJReW44RHc2elROa0N4VkNBR1VjWFVlYUFKYmdlQWZfaXg2Z092MWNEb1YxR3huemd6dGR6eG1uQQ?oc=5", "source_name": "Business Wire", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQVXZmQVp5S1FKVi03dzg1Z1FVLWM4WXpiRDRJOExQOXJHdFpGdGdQVXpIZWN0V0RUbWRicEQ0dlZFVkt1U3A0ekZseUVvOW9uMFNJVjNrczJaUEVJZUFJNnhWb2lNa1F2RGRTQkV1aS1xZm9jMXdWU3AxYkRvLU5UTXJxMzBHY25GcmlkcUM1NEZnMDNqcjFF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seven new Immunome hires get options on 282,000 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOLUpXRHZ0Z2dyYlczdzVPRkw5VEg1UkRyRnVHdjJuQVlzellWNGc4djNybTA2eEZNb21nZjBsZjh5ZmFaVHRDT1VjQU1TUWpJMHVZbmtzQjh1RTVxZEt0TU1FeFlVbkt2TWp1R2tZLTJibzRzXzdLYnFHVnVXMHI5UUpTTzVqRHBPQXV5cVdVMXp3SzFCSUNjNEZSbkp5bjlxZThWLVlfdDF1VUMxTHk4TDRYQkdrNmdaRUh5SHlHZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQbHJpWHhFZGFSUFJCcnZUelRvX3NKY2JxUXpTZW1rMjVaMXVmTUd1RXgzVTFyR3JhamJVeUVuVTd1bG9kU0M1X2VXSm9xWm1tM0JJTWItMWd4eG5PQTJlNkdJZ2UybGljOEoxVEx5ZGhYbVZ6ZXMwWjJOb1hlUmh2b2tB?oc=5", "source_name": "Market source", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 58, "sentiment_summary": {"positive": 17, "negative": 3, "neutral": 38, "score": 57, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "earnings", "label": "Earnings", "weight": 3.71, "count": 9}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 23.35, "latest_week": "2026-07-10", "one_week_move": -1.1, "four_week_move": 27.0, "twelve_week_move": -5.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.239412, "market_dynamics_buy_signal": false, "relative_strength": 10.822425, "fair_value_gap": 65.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 45.5773, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.1% over one week, +27.0% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 9}, {"label": "MT Newswires", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 7}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.1% over one week, +27.0% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why Immunome (IMNM) Is Down 8.2% After FDA Accepts Varegacestat NDA With Strong Phase 3 Data"}], "updated_at": "2026-07-17T18:48:10.917047+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}